David Dobbs
Contributing writer
The Transmitter
From this contributor
Remembering Mark Hallett, leader in transcranial magnetic stimulation
The long-time NINDS researcher, best known for studying movement disorders, has died at age 82.
Remembering Mark Hallett, leader in transcranial magnetic stimulation
The new history of autism, part III
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
The new history of autism, part II
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
The new history of autism, part I
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
Rethinking regression in autism
The loss of abilities that besets some toddlers with autism is probably less sudden and more common than anyone thought.
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.